You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Actelion Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Actelion
International Patents:247
US Patents:15
Tradenames:6
Ingredients:6
NDAs:8
PTAB Cases with Actelion as petitioner: See PTAB cases with Actelion as petitioner

Drugs and US Patents for Actelion

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion TRACLEER bosentan TABLET, FOR SUSPENSION;ORAL 209279-001 Sep 5, 2017 RX Yes Yes 7,959,945 ⤷  Try a Trial Y ⤷  Try a Trial
Actelion UPTRAVI selexipag TABLET;ORAL 207947-002 Dec 21, 2015 AB RX Yes Yes 10,821,108 ⤷  Try a Trial Y ⤷  Try a Trial
Actelion OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 AB RX Yes Yes 8,367,685 ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Actelion

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actelion ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 5,472,969 ⤷  Try a Trial
Actelion ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 5,525,616 ⤷  Try a Trial
Actelion TRACLEER bosentan TABLET;ORAL 021290-002 Nov 20, 2001 5,292,740 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ACTELION drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 10 mg ➤ Subscribe 2017-10-18
➤ Subscribe for Oral Suspension 32 mg ➤ Subscribe 2019-02-08

Supplementary Protection Certificates for Actelion Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1400518 93266 Luxembourg ⤷  Try a Trial PRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519
1345920 SPC/GB14/018 United Kingdom ⤷  Try a Trial PRODUCT NAME: MACITENTAN, WHICH IS N-(5-(4-BROMOPHENYL)-6-(2((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE; REGISTERED: UK EU/1/13/893 20131220
1345920 502 Finland ⤷  Try a Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.